PD 123319
|
|
|
- CAS号:
- 130663-39-7
- 英文名:
- PD 123319 ditrifluoroacetate
- 英文别名:
- CS-953;PD 123,319;PD123319 TFA;PD123319, >=98%;(S)-(+)-PD 123319;ditrifluoroacetate;PD-123319 TFA salt;PD-123319 free base;PD 123319 ditrifluor;PD 123319, 10 mM in DMSO
- 中文名:
- PD 123319
- 中文别名:
- 化合物PD123319;化合物PD123319,10 MM DMSO 溶液;(6S)-1-[[4-(二甲氨基)-3-甲基苯基]甲基]-5-(2,2-二苯乙酰基)-4,5,6,7-四氢-1H-咪唑并[4,5-C]吡啶-6-羧酸
- CBNumber:
- CB3669147
- 分子式:
- C31H32N4O3
- 分子量:
- 508.61
- MOL File:
- 130663-39-7.mol
|
|
|
PD 123319化学性质
-
沸点:
-
775.8±60.0 °C(Predicted)
-
|
-
密度:
-
1.22±0.1 g/cm3(Predicted)
-
|
-
储存条件:
-
2-8°C
-
|
-
溶解度:
-
H2O: 12 mg/mL
-
|
-
形态:
-
powder
-
|
-
酸度系数(pKa):
-
2.80±0.20(Predicted)
-
|
-
水溶解性:
-
Soluble to 100 mM in water
-
|
PD 123319性质、用途与生产工艺
PD123319是一种有效的，选择性AT2血管紧张素Ⅱ受体拮抗剂， IC50为34 nM。
PD123319在多种不同组织中所用受体的两个子类中表现不同。
125I--AII特异性标记两类结合在膜制备牛肾上腺glomerulosa细胞位点。第一类（DuP-753敏感）代表约85％的总结合位点，并对DUP-753具有高亲和力（IC 50为92.9 nM）。 PD-123319不会对
125 I-AII结合到本位点有任何影响。第二类结合位点对PD-123319更敏感， IC 50是6.9 nM，并且对DUP-753的亲和力低得多（IC50值约10 mM）。
PD123319对脑血流量的自我调节没有影响。急性AT2受体阻断不影响脑血流自动调节功能。 PD 123319静脉给药导致了高血压大鼠中瞬时的剂量依赖性的MAP增加，3毫克/千克的PD123319导致MAP维持约为7.4分钟。
PD123319是一种有效的，选择性AT2血管紧张素Ⅱ受体拮抗剂， IC50为34 nM。
| Target | Value |
|
AT2 receptor
|
34 nM
|
PD123319在多种不同组织中所用受体的两个子类中表现不同。
PD123319对脑血流量的自我调节没有影响。急性AT2受体阻断不影响脑血流自动调节功能。 PD 123319静脉给药导致了高血压大鼠中瞬时的剂量依赖性的MAP增加，3毫克/千克的PD123319导致MAP维持约为7.4分钟。
PD 123319
上下游产品信息
上游原料
下游产品
| 更新日期 | 产品编号 | 产品名称 | CAS编号 | 包装 | 价格 |
|---|
| 2025/05/22 | HY-10259A | PD 123319 ditrifluoroacetate | 130663-39-7 | 1 mg | 405元 |
| 2025/05/22 | HY-10259A | PD 123319
PD 123319 ditrifluoroacetate | 130663-39-7 | 5mg | 893元 |
130663-39-7, PD 123319 相关搜索:
- Angiotensin
- Inhibitors
- 抑制剂
- 合成有机化合物配体
- 小分子抑制剂，天然产物
- 内分泌与激素
- C31H32N4O32CF3CO2H
- (6S)-1-[[4-(二甲氨基)-3-甲基苯基]甲基]-5-(2,2-二苯乙酰基)-4,5,6,7-四氢-1H-咪唑并[4,5-C]吡啶-6-羧酸
- 化合物PD123319,10 MM DMSO 溶液
- 化合物PD123319
- 130663-39-7
- PD 123319, 10 mM in DMSO
- (S)-(+)-PD 123319|||PD123319
- PD-123319 free base
- PD 123319 ditrifluor
- PD 123319 ditrifluoroacetate USP/EP/BP
- PD-123319 TFA salt
- CS-953
- PD123319, >=98%
- 1-[[4-(dimethylamino)-3-methylphenyl]methyl]-5-(2,2-diphenylacetyl)-6,7-dihydro-4H-imidazo[4,5-c]pyridine-6-carboxylic acid
- PD123319 TFA
- (6S)-1-[[4-(Dimethylamino)-3-methylphenyl]methyl]-5-(2,2-diphenylacetyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-6-carboxylic acid
- (S)-(+)-PD 123319
- ditrifluoroacetate
- 1H-IMidazo[4,5-c]pyridine-6-carboxylic acid, 1-[[4-(diMethylaMino)-3-Methylphenyl]Methyl]-5-(2,2-diphenylacetyl)-4,5,6,7-tetrahydro-, (6S)-
- 1H-Imidazo(4,5-C)pyridine-6-carboxylic acid, 1-((4-(dimethylamino)-3-methylphenyl)methyl)-5-(diphenylacetyl)-4,5,6,7-tetrahydro-, (S)-
- (6S)-1-[4-Dimethylamino-3-methylbenzyl]-5-diphenylacetyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-6α-carboxylic acid
- (6S)-1-[4-(Dimethylamino)-3-methylbenzyl]-5-(diphenylacetyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-6-carboxylic acid
- (6S)-1-[[4-(Dimethylamino)-3-methylphenyl]methyl]-5-(diphenylacetyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-6α-carboxylic acid
- s-(+)-1-[(4-(dimethylamino)-3-methylphenyl)methyl]-5-(diphenylacetyl)-4,5,6,7-tetrahydro-1h-imidazo[4,5-c]pyridine-6-carboxylic acid ditrifluoroacetate
- pd 123,319 di(trifluoroacetate) salt
- 1-((4-(Dimethylamino)-3-methylphenyl)methyl)-5-(diphenylacetyl)-4,5,6,7-tetrahydro-1H-imidazo[4.5-c]pyridine-6-carboxyli
- PD 123,319 DITRIFLUOROACETATE POTENT AND SELECTIVE
- S(+)-1-[[4-(DIMETHYLAMINO)-3-METHYLPHENYL]METHYL]-5-(DIPHENYLACETYL)-4,5,6,7-TETRAHYDRO-1H-IMIDAZOL[4,5-C]PYRIDINE-6-CARBOXYLIC ACID DITRIFLUOROACETATE
- PD 123,319 DITRIFLUOROACETATE
- PD 123,319
- (3S)-9-[(4-DIMETHYLAMINO-3-METHYL-PHENYL)METHYL]-4-(2,2-DIPHENYLACETYL)-4,7,9-TRIAZABICYCLO[4.3.0]NONA-7,10-DIENE-3-CARBOXYLIC ACID
- 1-[[4-(DIMETHYLAMINO)-3-METHYLPHENYL]METHYL]-5-(DIPHENYLACETYL)-4,5,6,7-TETRAHYDRO-1H-IMIDAZO[4,5-C]PYRIDINE-6-CARBOXYLIC ACID DITRIFLUOROACETATE